Increased release of interleukin-12p40 in MS: Association with intracerebral inflammation

Neurology

Volumn 51, Issue 3, 1998, Pages 753-758

  Fassbender, Klaus ^a   Ragoschke, A ^b   Rossol, S ^b   Schwartz, A ^b   Mielke, O ^b   Paulig, A ^b   Hennerici, M ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN PROTEIN; INTERLEUKIN 12; PROTEIN P40; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE DURATION; DISEASE SEVERITY; ENCEPHALITIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FOLDING;

EID: 0031721520     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.51.3.753     Document Type: Article

References (28)

1. Miller DH, Rudge P, Johnson G, et al. Serial gadolinium enhanced magnetic resonance in multiple sclerosis. Brain 1988; 111:927-939.
2. Tsukada N, Miyagi K, Matsuda M, Yanagisawa N. Increased levels of intercellular adhesion molecule-1 in multiple sclerosis and human T-lymphotropic virus type 1-associated myelopathy. Ann Neurol 1993;33:646-649.
3. Franciotta DM, Grimaldi LME, Martino GV, et al. Tumornecrosis factor in serum and cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol 1989;26:787-789.
4. Maimone D, Gregory S, Arnason BGW, Reder AT. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol 1991;32:67-74.
5. Gallo P, Piccinno MG, Krzalic L, Tavolato B. Tumor necrosis factor alpha (TNF-alpha) and neurological diseases: failure in detecting TNF-alpha in the cerebrospinal fluid from patients with multiple sclerosis, AIDS dementia complex, and brain tumor. J Neuroimmunol 1989;23:41-44.
6. Peter JB, Boctor FN, Tourtelotte WW. Serum and CSF levels of IL-2, sIL2R, TNF-α, and IL-1β in chronic progressive multiple sclerosis: expected lack of clinical utility. Neurology 1991;41:121-123.
7. Whitaker JN, Herman PK. Human myelin basic protein peptide 69-89: immunochemical features and use in immunoassays of cerebrospinal fluid. J Neuroimmunol 1988;19:47-57.
8. Fassbender K, Schmidt R, Möβner R, et al. Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal (HPA)-axis in multiple sclerosis: association with cerebral inflammation. Arch Neurol 1998;55:66-72.
9. Gubler U, Chua AO, Schoenhaut DS, et al. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci USA 1991;88:4143-4147.
10. Hendrzak JA, Brunda MJ. Interleukin-12: biologic activity, therapeutic utility, and role in disease. Lab Invest 1995;72: 619-637.
11. D'Andrea A, Rengaraju M, Valiante NM, et al. Production of natural killer cell stimulation factor (interleukin-12) by peripheral blood mononuclear cells. J Exp Med 1992;176:1387-1398.
12. Trinchieri G. Interleukin-12 and its role in generation of TH1 cells. Immunol Today 1993;14:335-338.
13. H2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-173.
14. Becher B, Dodelet V, Fedorowicz V, Antel JP. Soluble tumor necrosis factor receptor inhibits interleukin 12 production by stimulated human adult microglial cells in vitro. J Clin Invest 1996;98:1539-1543.
15. Manetti R, Parronchi P, Giudizi MG, et al. Natural killer cell stimulatory factor (interleukin-12 [IL-12]) induces T helper 1 (Th1)-specific immune responses and inhibits the development of IL-4 producing Th cells. J Exp Med 1993;177:1199-1204.
16. Trembleau S, Germann T, Gately MK, Adorini L. The role of IL-12 in the induction of organ-specific autoimmune diseases. Immunol Today 1995;16:383-386.
17. Selmaj K, Raine CS, Cross AH. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol 1991;30:694-700.
18. Windhagen A, Newcombe J, Dangond F, et al. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med 1995;182:1985-1996.
19. Smith T, Hewson AK, Kingsley CI, Leonard JP, Cuzner ML. Interleukin-12 induces relapse in experimental allergic encephalomyelitis in the Lewis rat. Am J Pathol 1997;150:1909-1917.
20. Leonard JP, Waldburger KE, Goldman SJ. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med 1995;181:381-386.
21. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
22. Fassbender K, Ries S, Schminke U, Schneider S, Hennerici M. Inflammatory cytokines in CSF in bacterial meningitis: association with altered blood flow velocities in basal cerebral arteries. J Neurol Neurosurg Psychiatry 1996;61:57-61.
23. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
24. Kermode AG, Thompson AJ, Tofts P, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis: pathogenetic and clinical implications. Brain 1990;113:1477-1489.
25. Barkhof F, Frequin STFM, Hommes OR, et al. A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Neurology 1992;42:63-67.
26. Drulovic J, Mostarica-Stojkovic M, Levic Z, Stojsavljevic N, Pravica V, Mesaros S. Interleukin-12 and tumor necrosis factor-α levels in cerebrospinal fluid of multiple sclerosis patients. J Neurol Sci 1997;147:145-150.
27. Nicoletti F, Patti F, Cocuzza C, et al. Elevated serum levels of interleukin 12 in chronic progressive multiple sclerosis. J Neuroimmunol 1996;70:87-90.
28. Gately MK, Carvajal DM, Connaughton SE, et al. Interleukin-12 antagonist activity of mouse interleukin-12 p40 homodimer in vitro and in vivo. Ann NY Acad Sci 1996; 795:1-12.